文献速递心脑血管急症

印度急诊医师启动溶栓治疗ST段抬高型心肌梗死患者的结局:一项横断面研究

Outcomes of ST-elevation myocardial infarction (STEMI) patients undergoing thrombolysis initiated by emergency physicians: A cross-sectional study from India.
PubMed 文献 · Am J Emerg Med · 2025-07-07
一句话结论急诊医师启动溶栓治疗STEMI的溶栓成功率为73%,30天主要不良心血管事件发生率为15.9%。

该横断面研究纳入印度中部一家三级公立医院连续245例接受急诊医师启动溶栓治疗的STEMI患者,评估短期临床结局。主要结局为成功再灌注的患病率,次要结局为30天主要不良心血管事件(MACE)。结果显示溶栓成功率为73%,症状发作12小时内就诊者成功率更高(OR=3.15,p=0.006)。30天MACE发生率为15.9%。无医疗保险、Killip III/IV级、时间窗>3小时和急诊溶栓失败为独立危险因素,药物侵入性治疗为独立保护因素。

要点

  • 245例STEMI患者接受急诊医师启动溶栓,成功再灌注率为73%。
  • 症状发作12小时内就诊与溶栓成功独立相关(OR=3.15,p=0.006)。
  • 30天MACE发生率为15.9%。
  • 无医疗保险、Killip III/IV级、时间窗>3小时和急诊溶栓失败为MACE独立危险因素。
  • 药物侵入性治疗为MACE独立保护因素。

适用人群与场景

  • 印度中部一家三级公立医院连续245例接受急诊医师启动溶栓治疗的STEMI患者,研究周期两年。

处置流程与药物剂量

  • 由急诊医师启动溶栓治疗,溶栓药物包括替奈普酶(tenecteplase)。

红旗征与不能漏的情况

  • Killip III/IV级为30天MACE独立危险因素。
  • 时间窗>3小时为30天MACE独立危险因素。
  • 急诊溶栓失败为30天MACE独立危险因素。

研究设计与关键结果

  • 研究类型为横断面研究,样本量245例,人群为印度中部三级公立医院连续STEMI接受急诊医师启动溶栓治疗的患者。
  • 主要结局:溶栓成功率为73%。
  • 症状发作12小时内就诊者溶栓成功率更高(OR=3.15,p=0.006)。
  • 使用替奈普酶作为溶栓药物显示溶栓成功率有升高趋势(OR=5.60,p=0.06)。
  • 次要结局:30天MACE发生率为15.9%。
  • 无医疗保险、Killip III/IV级、时间窗>3小时和急诊溶栓失败为30天MACE独立危险因素;药物侵入性治疗为独立保护因素。

证据类型、等级与局限

  • 证据类型:横断面研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 急诊医师可在资源有限环境下为STEMI患者启动溶栓治疗,溶栓成功率73%、30天MACE发生率15.9%。
  • 作者认为早期就诊、使用纤维蛋白特异性溶栓药物和药物侵入性治疗与更好的结局相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: This cross-sectional study assessed the short-term clinical outcomes of patients with ST-Elevation Myocardial Infarction (STEMI) receiving emergency physician (EP)-initiated thrombolysis at a tertiary care public hospital in central India.

METHODS: The study included 245 consecutive STEMI patients treated with thrombolysis using EPs over two years. The primary outcome was the prevalence of successful reperfusion, and the secondary outcome included 30-day major adverse cardiac events (MACE).

RESULTS: Successful thrombolysis was achieved in 73 % of patients, with a higher success rate among patients presenting within 12 h of symptom onset (OR = 3.15, p = 0.006). The use of tenecteplase as a thrombolytic agent showed a trend towards higher success (OR = 5.60, p = 0.06). The 30-day MACE occurred in 15.9 % of the patients. The absence of health insurance, Killip class III/IV, window period >3 h, and failed ED thrombolysis were independent risk factors. Pharmaco-invasive therapy emerged as an independent protective factor against MACE.

CONCLUSIONS: This study demonstrates that EPs can administer thrombolysis in STEMI with reasonable success and safety, even in resource-limited settings. Early presentation, use of fibrin-specific thrombolytics, and pharmaco-invasive therapy are associated with better outcomes.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Agrawal N, Duraiswami K, Agrawal S, et al. Outcomes of ST-elevation myocardial infarction (STEMI) patients undergoing thrombolysis initiated by emergency physicians: A cross-sectional study from India. Am J Emerg Med. 2025. PMID: 40639307. doi:10.1016/j.ajem.2025.07.018

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。